Adamax Mechanism of Action
How Adamax works: receptor targets, signalling pathways, and molecular profile.
BDNF Upregulation and TrkB Receptor Activation
Adamax is structurally derived from Semax, a heptapeptide analog of the ACTH(4-10) fragment. Its primary mechanism of interest involves the modulation of brain-derived neurotrophic factor (BDNF) expression and activation of its primary receptor, TrkB. In rodent hippocampal models, Semax administration at 50 μg/kg produced a 1.4-fold increase in BDNF protein levels and a 1.6-fold increase in TrkB tyrosine phosphorylation. Adamax is investigated within this same experimental framework to assess whether the adamantyl modification prolongs or enhances these interactions through greater enzymatic stability.
Adamantyl Modification and Blood-Brain Barrier Penetration
The defining structural feature of Adamax relative to standard Semax is the adamantyl group at the C-terminus, derived from Peptide P21. Adamantane is a lipophilic, cage-like hydrocarbon structure that is hypothesized to enhance blood-brain barrier penetration by increasing lipophilicity and reducing polar surface area. The N-terminal acetyl group provides complementary protection against aminopeptidase enzymatic degradation, extending the in vivo half-life relative to unmodified Semax. Together these two modifications are the focus of Adamax preclinical research — they are not properties confirmed in human trials.
Downstream Signaling: MAPK/ERK and PI3K/Akt
Semax-derived peptides engage downstream intracellular cascades following TrkB receptor activation. In cell-based experimental systems, MAPK/ERK and PI3K/Akt signaling pathways are engaged — both associated with neuronal survival, protein synthesis, and synaptic remodeling. Additionally, the HGF/c-Met pathway has been implicated in Adamax-class compound research in the context of synaptogenesis and dendritic spine formation in APP/PS1 transgenic mouse models. These findings are preclinical and not consistent across all model systems.